Clinical Trials Using Anti-GPC3-CAR Autologous T Lymphocytes

Clinical trials are research studies that involve people. The clinical trials on this list are studying Anti-GPC3-CAR Autologous T Lymphocytes. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trial 1 of 1
  • Modified Immune Cells (GPC3-CAR T cells) for the Treatment of Relapsed or Refractory Pediatric Solid Tumors

    This phase I trial studies the side effects and best dose of GPC3-CAR T cells in treating pediatric patients with solid tumors that have come back or do not respond to treatment. This study combines two different ways of fighting cancer: antibodies and T cells. Antibodies are types of proteins that protect the body from infectious diseases and possibly cancer. T cells, also called T lymphocytes, are special infection-fighting blood cells that can kill other cells, including cells infected with viruses and tumor cells. In the laboratory, new genes called chimeric antigen receptors (CARs) are made from an antibody called GC33 that recognizes glypican-3, a protein found on solid tumors (GPC3-CAR). T cells genetically engineered with a GPC3-CAR may recognize cancer cells and kill them.
    Location: 2 locations